Sonrai Analytics will partner with the Precision Medicine Center (PMC) at Queen's University Belfast on a program to provide a tool for cancer diagnosis.

Secretary of State for Health and Human Services Matt Hancock announced today that the AI Award provided £ 140 million over four years to facilitate testing and evaluation of artificial technology intelligence that has achieved the NHS's long-term goals.

Seven new special Sonrai Analytics tasks will be completed in the coming months. A team of experts will develop and train new artificial intelligence algorithms on the cloud platform, where pathologists can upload biopsy images and "run" against the algorithms for faster and more accurate results.

LumiThera now says it has completed the acquisition of Diopsys for an undisclosed amount.

The acquisition of Pine Brook, a New Jersey-based manufacturer of medical devices for electrophysiology, Diopsys, was announced earlier in November. 11, 2021. Through the agreement, Diopsys shareholders will also acquire shares in LumiThera and Diopsys will become a wholly owned subsidiary of the Seattle-based company.

LumiThera will add the additional diagnostic and monitoring platform Valeda Lighting System to its platform for managing eye damage and disease. The current LumiThera platform uses photobiomodulation to treat age-related macular degeneration. Diopsys' established US sales will join LumiThera's EU sales team to serve a larger global presence of eye care professionals.

Inventya Grants has completed the merger with Cresco Innovation. The aim of this merger is to further improve their joint offering to support innovation and growth to clients through other grant writing services.

With more than a decade of experience writing grants, the Cresco team of bidders has received more than £ 30 million in grant funding for clients over the last three years.

Aldo De Leonibus, CEO of Inventya Limited, said: “We are pleased to have completed this partnership because it allows us to offer our expanded customer base enhanced services to support our mission to help new businesses succeed. products and services.United UK and international markets through finance, finance, tax relief for R&D and consulting.

Johnson & Johnson announced that DePuy Synthes, an orthopedic company of the medical giant, had bought CrossRoads Extremity Systems for an undisclosed amount.
Tennessee-based CrossRoads manufactures implants and instruments for lower limb procedures, such as certain spine and foot surgeries. In an announcement, J&J said operations for "conditions such as stabbed sticks and hammers are one of the fastest-growing features of state-of-the-art orthopaedic and podiatric procedures," as in the United States.